Previous 10 | Next 10 |
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announced that it has submitted ...
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announced that it has submit...
Positive preliminary data showed SENS-401 has a clinically significant effect on the preservation of residual hearing after cochlear implantation in all adult patients treated so far On the 19 th of June, Sensorion announced that the patients treated with SENS-401 showed presence ...
SENS-401 first-in-class drug candidate showed promising preliminary data in POC Phase 2a study to prevent residual hearing loss after cochlear implantation Preliminary results demonstrated 100% patients treated with SENS-401 showed presence of SENS-401 in perilymph at therapeutic conc...
SENS-401 update on the POC Phase 2a clinical study evaluating SENS-401 in association with cochlear implantation KOL Webinar with Professor Yann Nguyen to be held on Wednesday July 5, 2023, at 11am Eastern Time Key SENS-401 POC Phase 2a preliminary data on presence of SENS-401...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces today the results of resolutions presented at its Combined General Meeting (CGM), held on May 24, 2023, and made them ...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in the ASGCT Annual Meeting taking place on May 16-20, 2023, in Los Angeles, USA. Gérald...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wedne...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a symposium at the 3 rd ISIET’s International Symposium on Inner Ear Therapeutics, an e...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation in two investor conferences in April 2023. CEO Nawal Ouzren will attend, virtually,...
News, Short Squeeze, Breakout and More Instantly...
RiverNorth Flexible Municipal Income Fund Inc. Company Name:
RFM Stock Symbol:
NYSE Market:
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that the independent Data Safety Mon...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the publication of new positive data...
2024-07-14 03:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...